| Ning Li,Yutao Gao,Wei Zhang,Xiaoguang Li,Bin Li,Haimei Tian,Yanfen Li,Lingying Wu. Comparative analysis of ATP-based tumor chemosensitivity assay-directed chemotherapy versus physician-decided chemotherapy in platinum-resistant recurrent ovarian cancer. Oncol Transl Med, 2017, 3: 225-230. |
| Comparative analysis of ATP-based tumor chemosensitivity assay-directed chemotherapy versus physician-decided chemotherapy in platinum-resistant recurrent ovarian cancer |
| Received:October 02, 2017 Revised:December 07, 2017 |
| View Full Text View/Add Comment Download reader |
| KeyWord:epithelial ovarian cancer; platinum-resistance; recurrence; ATP-based tumor chemosensitivity assay (ATP-TCA) |
| Author Name | Affiliation | E-mail | | Ning Li | Department of Gynecological Oncology, National Cancer Center/Cancer Hospital, Chinese Academy of Medical Sciences and Peking Union Medical College, Beijing 100021, China | liningnci@126.com | | Yutao Gao | Department of Gynecological Oncology, National Cancer Center/Cancer Hospital, Chinese Academy of Medical Sciences and Peking Union Medical College, Beijing 100021, China | | | Wei Zhang | Biological Testing Center, National Cancer Center/Cancer Hospital, Chinese Academy of Medical Sciences and Peking Union Medical College, Beijing 100021, China | | | Xiaoguang Li | Department of Gynecological Oncology, National Cancer Center/Cancer Hospital, Chinese Academy of Medical Sciences and Peking Union Medical College, Beijing 100021, China | | | Bin Li | Department of Gynecological Oncology, National Cancer Center/Cancer Hospital, Chinese Academy of Medical Sciences and Peking Union Medical College, Beijing 100021, China | | | Haimei Tian | Biological Testing Center, National Cancer Center/Cancer Hospital, Chinese Academy of Medical Sciences and Peking Union Medical College, Beijing 100021, China | | | Yanfen Li | Cancer Hospital, Chinese Academy of Medical Sciences | | | Lingying Wu | Department of Gynecological Oncology, National Cancer Center/Cancer Hospital, Chinese Academy of Medical Sciences and Peking Union Medical College, Beijing 100021, China | wulingying@csco.org.cn |
|
| Hits: 7753 |
| Download times: 8815 |
| Abstract: |
| Objective The aim of the study was to evaluate the role of ATP-based tumor chemosensitivity assay
(ATP-TCA) in patients with platinum-resistant recurrent ovarian cancer (PRROC).
Methods A total of 43 patients with PRROC who underwent chemotherapy based on the results of ATPTCA
in the Cancer Hospital, Chinese Academy of Medical Sciences were included in the present study. As
controls, we selected another 43 patients with PRROC who were treated at the physician’s discretion within
the same time period and had the same clinical characteristics as the patients in the ATP-TCA group. Logrank
test and Cox proportional hazards model were adopted for analysis.
Results A total of 86 patients were retrospectively analyzed in the present study. Patients were routinely
monitored to evaluate the rate of progression-free survival (PFS). The median follow-up time was 13
months. The PFS for the ATP-TCA and control groups was 5 and 3 months, respectively (P = 0.027).
Multivariate analysis showed that the type of treatment was an independent prognostic factor for PFS (P =
0.040; HR: 0.623; 95% CI: 0.313–0.973). Subgroup analysis showed that among patients with a treatmentfree
interval (TFI) of ≥ 3 months (n = 50), those in the ATP-TCA group had longer PFS than those in the
control group (7 vs 4 months, P = 0.010). Meanwhile, the median PFS of patients who underwent ≤ 2 prior
chemotherapy regimens (PCR, n = 52) in the ATP-TCA and control groups was 6 months and 4 months,
respectively (P = 0.025).
Conclusion ATP-TCA-directed chemotherapy might improve the PFS in PRROC. In particular, the
survival benefit from ATP-TCA is higher in patients with a TFI of ≥ 3 months or treated with ≤ 2 PCR. |
| Close |
|
|
|